Stocks Hitting 52-Week Lows

shares touched a new 52-week low of $7.366 following Phase 3 trial failure. Chimerix announced in a press release that a Phase 3 study for its SUPPRESS of brincidofovir did not achieve a primary endpoint for the prevention of clinically significant cytomegalovirus infection through Week 24 after transplant.

shares declined 0.67 percent to reach a new 52-week low of $2.95. Capricor Therapeutics shares have dipped 19.95 percent over the past 52 weeks, while the S&P 500 index has dropped 1.33 percent in the same period.

shares fell 2.39 percent to reach a new 52-week low of $4.91. Hallador Energy's trailing-twelve-month ROA is 5.94 percent.

shares fell 10.40 percent to touch a new 52-week low of $5.67. DHX Media shares have declined 23.76 percent over the past 52 weeks, while the S&P 500 index has dropped 1.33 percent in the same period.